Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma

Érika Cosset,Sten Ilmjärv,Valérie Dutoit,Kathryn Elliott,Tami von Schalscha,Maria F Camargo,Alexander Reiss,Toshiro Moroishi,Laetitia Seguin,German Gomez,Jung-Soon Moo,Olivier Preynat-Seauve,Karl-Heinz Krause,Hervé Chneiweiss,Jann N Sarkaria,Kun-Liang Guan,Pierre-Yves Dietrich,Sara M Weis,Paul S Mischel,David A Cheresh
DOI: https://doi.org/10.1016/j.ccell.2017.10.016
IF: 50.3
2017-12-11
Cancer Cell
Abstract:While molecular subtypes of glioblastoma (GBM) are defined using gene expression and mutation profiles, we identify a unique subpopulation based on addiction to the high-affinity glucose transporter, Glut3. Although Glut3 is a known driver of a cancer stem cell phenotype, direct targeting is complicated by its expression in neurons. Using established GBM lines and patient-derived stem cells, we identify a subset of tumors within the "proneural" and "classical" subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression. This defined subpopulation of GBM is highly sensitive to agents that disrupt this pathway, including the integrin antagonist cilengitide, providing a targeted therapeutic strategy for this unique subset of GBM tumors.
What problem does this paper attempt to address?